Amgen Inc. (NASDAQ:AMGN) is also advancing xaluritamig, a first-in-class STEAP1 CD3 bispecific molecule, into Phase III clinical development for post-taxane metastatic castrate-resistant prostate ...
Amgen Inc. (NASDAQ:AMGN) 45th Annual TD Cowen Health Care Conference Transcript March 5, 2025 9:10 AM ETCompany ParticipantsJay Bradner - Executive ...
Amgen: Xaluritamig is a STEAP1 x CD3 XmAb 2+1 bispecific T-cell engager that our partner Amgen is advancing for the treatment of patients with prostate cancer. In the fourth quarter of 2024 ...
James Bradner; Executive Vice President - Research and Development; Amgen Inc Peter Griffith ... showing impressive efficacy and hard to treat small cell lung cancer and xaluritamig advancing into ...
THOUSAND OAKS, Calif., Feb. 4, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2024 versus comparable periods in 2023.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results